Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
NCT01990846 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68
Last updated 2015-03-11
Summary
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
Conditions
Interventions
- DRUG
-
Flufirvitide 3
- DRUG
-
Placebo for Flufirvitide-3
Sponsors & Collaborators
-
Autoimmune Technologies, LLC
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2015-02-28
- Completion
- 2015-02-28
Countries
- United States
Study Locations
More Related Trials
-
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
NCT00800605 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model
NCT05507567 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
NCT00841763 ·Status: COMPLETED ·Phase: PHASE3
-
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
NCT05572450 ·Status: COMPLETED ·Phase: NA
-
A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)
NCT07349017 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine
NCT01265914 ·Status: COMPLETED ·Phase: PHASE1
-
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
NCT06160531 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
NCT01776541 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
NCT00434733 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
NCT00971906 ·Status: COMPLETED ·Phase: PHASE3
-
First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP
NCT06460064 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study
NCT00644540 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
NCT00970177 ·Status: COMPLETED ·Phase: PHASE3
-
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
NCT07240922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
NCT07159763 ·Status: RECRUITING ·Phase: PHASE3
-
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
NCT01701752 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents
NCT01052402 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine
NCT00197223 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation
NCT00946179 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
NCT00973349 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
NCT00395174 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases
NCT00519064 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
NCT00537524 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
NCT01144299 ·Status: COMPLETED ·Phase: PHASE3
-
A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults
NCT00920374 ·Status: COMPLETED ·Phase: PHASE3